ArticlePharmacological reports : PR2022

The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.

Stanton Tam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.